Rollprint adds director of technical services

New position created to add r&d capacity and support customers

Rollprint Packaging Products, the US supplier of packaging materials for the healthcare and food industries, has welcomed Dr Henk Blom as director of technical services. He reports to Doug Dodrill, vice president of technology.

‘As the demand for Rollprint products continues to grow, it was important to support our customers with additional r&d capability so we created the new position,’ Dodrill said.

Having spent the past 12 years at Baxter Healthcare Corporation, Blom brings significant medical device technical expertise to the position.

‘Henk’s background enables him to look at the big picture – materials, distribution, processing, failure analysis, etc. – to help our customers find ideal packaging solutions for their specific product requirements,’ added Dodrill.

You may also like

Packaging

Easy-to-open Barex replacement takes on single-dose applications

Peelable Exponent is designed for hard-to-hold and sensitive chemicals
Packaging

Rollprint introduces Exponent clear flexible film for high-barrier pharmaceutical applications

The result of a collaboration between Rollprint and Ineos
Packaging

Rollprint Ghost technology thwarts counterfeiters

The process creates a repeating watermark embedded in flexible packaging materials
Packaging

Colour-changing sealant enhances pack security

Allows a film of one colour to transfer a peel indicator of a different colour
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
Subscribe now